Nivolumab & Ipilimumab is named as a drug or biological intervention in 3 clinical trials in our USA and UK trial registers, 1 of which is recruiting. Lead sponsors include Scancell Ltd (1), Lantern Pharma Inc. (1) and Vivace Therapeutics, Inc (1). Registered phases: Phase 1/2 and Phase 3. Conditions studied include Melanoma (Skin Cancer); Advanced Melanoma; Metastatic Melanoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor, Adult, Mesothelioma, NSCLC |
Phase 1/2 | Recruiting |
| NCT07815574 | iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma (ClinicalTrials.gov ↗) Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma |
Phase 3 | Not yet open |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors Advanced Solid Tumor, Metastatic Solid Tumor, GBM |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Melanoma (Skin Cancer) | 1 |
| Advanced Melanoma | 1 |
| Metastatic Melanoma | 1 |
| Skin Cancer | 1 |
| Advanced Solid Tumor | 1 |
| Metastatic Solid Tumor | 1 |
| GBM | 1 |
| TNBC - Triple-Negative Breast Cancer | 1 |
| Solid Tumor, Adult | 1 |
| Mesothelioma | 1 |
| NSCLC | 1 |
| Lead sponsor | Trials |
|---|---|
| Scancell Ltd | 1 |
| Lantern Pharma Inc. | 1 |
| Vivace Therapeutics, Inc | 1 |
| Register | Nivolumab & Ipilimumab trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nivolumab & Ipilimumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nivolumab & Ipilimumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.